目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 KEY STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key secondary sources
2.2.1.2 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
2.3.2 TOP-DOWN APPROACH
2.4 DATA TRIANGULATION
2.5 MARKET SHARE ASSESSMENT
2.6 RESEARCH ASSUMPTIONS
2.6.1 PARAMETRIC ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 BLOOD GAS ANALYZERS MARKET OVERVIEW
4.2 BLOOD GAS ANALYZERS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
4.3 BLOOD GAS ANALYZERS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION)
4.4 BLOOD GAS ANALYZERS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
4.5 BLOOD GAS ANALYZERS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
4.6 BLOOD GAS ANALYZERS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
4.7 BLOOD GAS ANALYZERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising incidence and prevalence of chronic and acute conditions
5.2.1.2 Advancements in blood gas analyzer technology
5.2.1.3 Inadequacy of alternative techniques
5.2.1.4 Growing demand for point-of-care blood gas analyzers
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement policies
5.2.2.2 Complex operations & interpretation of data
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in developing countries
5.2.3.2 Rising ICU and emergency department admissions
5.2.4 CHALLENGES
5.2.4.1 Availability of refurbished analyzers
5.2.4.2 Lack of data analysis software
5.3 PRICING ANALYSIS
5.3.1 AVERAGE SELLING PRICE TREND OF BLOOD GAS ANALYZERS, 2023-2025
5.3.2 AVERAGE SELLING PRICE TREND OF BLOOD GAS ANALYZERS, BY KEY PLAYER, 2023-2025
5.3.3 AVERAGE SELLING PRICE TREND OF BLOOD GAS ANALYZERS, BY REGION, 2023-2025
5.4 PATENT ANALYSIS
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS
5.7.2 IMPORT DATA (HS CODE 9027)
5.7.3 EXPORT DATA (HS CODE 9027)
5.8 ECOSYSTEM ANALYSIS
5.8.1 BLOOD GAS ANALYZERS MARKET: ROLE IN ECOSYSTEM
5.9 PORTER'S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 REGULATORY ANALYSIS
5.10.1 REGULATORY LANDSCAPE
5.10.1.1 North America
5.10.1.1.1 US
5.10.1.1.2 Canada
5.10.1.2 Europe
5.10.1.2.1 Germany
5.10.1.2.2 UK
5.10.1.2.3 France
5.10.1.2.4 Italy
5.10.1.3 Asia Pacific
5.10.1.3.1 China
5.10.1.3.2 Japan
5.10.1.3.3 India
5.10.1.4 Latin America
5.10.1.4.1 Brazil
5.10.1.4.2 Mexico
5.10.1.5 Middle East
5.10.1.6 Africa
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGIES
5.11.1.1 Electrochemical sensors
5.11.2 COMPLEMENTARY TECHNOLOGIES
5.11.2.1 Optical sensors
5.11.3 ADJACENT TECHNOLOGIES
5.11.3.1 Microfluidics
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 INVESTMENT & FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1: ROLE OF BLOOD GAS ANALYSIS IN EMERGENCY AND CRITICAL CARE
5.16.2 CASE STUDY 2: EVALUATION OF A HANDHELD BLOOD GAS ANALYZER IN INTENSIVE CARE SETTINGS
5.16.3 CASE STUDY 3: ROLE OF QUALITY MANAGEMENT SYSTEMS IN BLOOD GAS ANALYSIS
5.17 IMPACT OF AI/GENERATIVE AI ON BLOOD GAS ANALYZERS MARKET
5.17.1 INTRODUCTION
5.17.2 MARKET POTENTIAL OF AI
5.17.3 AI USE CASES
5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
5.17.5 FUTURE OF AI IN BLOOD GAS ANALYZERS MARKET
5.18 IMPACT OF 2025 US TARIFFS ON BLOOD GAS ANALYZERS MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 KEY IMPACT ON COUNTRY/REGION
5.18.4.1 North America
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON END-USE INDUSTRIES
5.18.5.1 Hospitals & ASCs
5.18.5.2 Clinics

6 BLOOD GAS ANALYZERS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 RECURRING USE OF CONSUMABLES TO DRIVE MARKET GROWTH
6.3 ANALYZERS
6.3.1 TECHNOLOGICAL ADVANCEMENTS IN ANALYZERS TO DRIVE ADOPTION
6.4 SERVICES
6.4.1 INCREASING FOCUS ON OPERATIONAL EFFICIENCY TO PROPEL MARKET EXPANSION

7 BLOOD GAS ANALYZERS MARKET, BY TYPE OF TESTING
7.1 INTRODUCTION
7.2 POINT-OF-CARE TESTING
7.2.1 IMPROVED USABILITY AND INNOVATIONS IN POC ANALYZERS TO BOOST ADOPTION OF POINT-OF-CARE TESTING
7.3 CONVENTIONAL TESTING
7.3.1 GROWING FOCUS ON AUTOMATION AND ACCURACY TO STRENGTHEN MARKET GROWTH

8 BLOOD GAS ANALYZERS MARKET, BY SAMPLE TYPE
8.1 INTRODUCTION
8.2 ARTERIAL BLOOD
8.2.1 HIGH UTILIZATION IN CRITICAL CARE SETTINGS TO SUPPORT MARKET GROWTH
8.3 VENOUS BLOOD
8.3.1 REDUCED INVASIVENESS OF VENOUS BLOOD SAMPLING TO BOOST MARKET ADOPTION
8.4 CAPILLARY BLOOD
8.4.1 RISING DEMAND FOR PATIENT-CENTRIC CAPILLARY SAMPLING TO DRIVE MARKET EXPANSION

9 BLOOD GAS ANALYZERS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 CRITICAL CARE MANAGEMENT
9.2.1 INCREASING BURDEN OF ACUTE CRITICAL ILLNESSES TO SUPPORT MARKET EXPANSION
9.3 RESPIRATORY CARE
9.3.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO DRIVE MARKET GROWTH
9.4 EMERGENCY CARE MANAGEMENT
9.4.1 INCREASING EMERGENCY DEPARTMENT VISITS TO PROPEL DEMAND FOR BLOOD GAS ANALYZERS
9.5 OTHER APPLICATIONS

10 BLOOD GAS ANALYZERS MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS & ASCS
10.2.1 EXPANDING HEALTHCARE INFRASTRUCTURE TO SPEED UP MARKET GROWTH
10.3 CLINICS
10.3.1 GROWING USE OF POINT-OF-CARE BLOOD GAS ANALYZERS TO SUPPORT MARKET GROWTH
10.4 OTHER END USERS

11 BLOOD GAS ANALYZERS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Increasing prevalence of chronic & respiratory diseases to drive market
11.2.3 CANADA
11.2.3.1 Rising demand for real-time diagnostics tools to drive market growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Favorable government policies to propel market growth
11.3.3 UK
11.3.3.1 Rising emergency department visits to drive market growth
11.3.4 FRANCE
11.3.4.1 Enhanced healthcare policies and strategic investments in diagnostics to boost market growth
11.3.5 ITALY
11.3.5.1 Growing chronic disease incidence and government initiatives to boost Italy's blood gas analyzers market
11.3.6 SPAIN
11.3.6.1 Growing public health initiatives to augment market growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Healthcare infrastructure development and disease burden to support market
11.4.3 JAPAN
11.4.3.1 Well-developed healthcare system and high geriatric population to aid market growth
11.4.4 INDIA
11.4.4.1 Initiatives to enhance access to healthcare and improve infrastructure to propel market growth
11.4.5 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Universal healthcare access to drive adoption in Brazil
11.5.3 MEXICO
11.5.3.1 Rising medical tourism to create strong demand for advanced diagnostic solutions
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.6.2 KINGDOM OF SAUDI ARABIA
11.6.2.1 Rising government healthcare expenditure to boost market
11.6.3 UAE
11.6.3.1 Improvements in healthcare infrastructure to support growth
11.6.4 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BLOOD GAS ANALYZERS MARKET
12.3 REVENUE ANALYSIS, 2020-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1 Company footprint
12.5.5.2 Region footprint
12.5.5.3 Product & service footprint
12.5.5.4 Type of testing footprint
12.5.5.5 Sample type footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.5.1 Detailed list of key startups/SMEs
12.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
12.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
12.7 COMPANY VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
12.7.2 COMPANY VALUATION
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT/SERVICE LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSIONS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 DANAHER CORPORATION
13.1.1.1 Business overview
13.1.1.2 Products/Services offered
13.1.1.3 Recent developments
13.1.1.3.1 Deals
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 WERFEN S.A.
13.1.2.1 Business overview
13.1.2.2 Products/Services offered
13.1.2.3 Recent developments
13.1.2.3.1 Product/Service launches
13.1.2.3.2 Expansions
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 SIEMENS HEALTHINEERS AG
13.1.3.1 Business overview
13.1.3.2 Products/Services offered
13.1.3.3 Recent developments
13.1.3.3.1 Deals
13.1.3.3.2 Expansions
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses & competitive threats
13.1.4 F. HOFFMANN-LA ROCHE LTD.
13.1.4.1 Business overview
13.1.4.2 Products/Services offered
13.1.4.3 Recent developments
13.1.4.3.1 Expansions
13.1.4.4 MnM view
13.1.4.4.1 Key strengths
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses & competitive threats
13.1.5 ABBOTT LABORATORIES
13.1.5.1 Business overview
13.1.5.2 Products/Services offered
13.1.5.3 MnM view
13.1.5.3.1 Key strengths
13.1.5.3.2 Strategic choices
13.1.5.3.3 Weaknesses & competitive threats
13.1.6 NOVA BIOMEDICAL
13.1.6.1 Business overview
13.1.6.2 Products/Services offered
13.1.6.3 Recent developments
13.1.6.3.1 Product/Service launches
13.1.6.3.2 Deals
13.1.6.3.3 Expansions
13.1.7 MEDICA CORPORATION
13.1.7.1 Business overview
13.1.7.2 Products/Services offered
13.1.8 TECHNO MEDICA CO., LTD.
13.1.8.1 Business overview
13.1.8.2 Products/Services offered
13.1.9 IDEXX LABORATORIES, INC.
13.1.9.1 Business overview
13.1.9.2 Products/Services offered
13.1.10 I-SENS, INC.
13.1.10.1 Business overview
13.1.10.2 Products/Services offered
13.2 OTHER PLAYERS
13.2.1 EDAN INSTRUMENTS, INC.
13.2.2 GUANGZHOU WONDFO BIOTECH CO., LTD.
13.2.3 LABTRON EQUIPMENT LTD.
13.2.4 CONVERGENT TECHNOLOGIES GMBH & CO. KG
13.2.5 ERBA GROUP
13.2.6 ESCHWEILER GMBH & CO.KG
13.2.7 SENSA CORE MEDICAL INSTRUMENTATION PVT. LTD.
13.2.8 CHENGDU SEAMATY TECHNOLOGY CO., LTD.
13.2.9 LABDEX LTD.
13.2.10 MEIZHOU CORNLEY HIGH-TECH CO., LTD.
13.2.11 PARAMEDICAL SRL
13.2.12 EAGLENOS SCIENCES, INC.
13.2.13 B&E BIO-TECHNOLOGY CO., LTD.
13.2.14 LABNICS LTD.
13.2.15 FISON INSTRUMENTS LTD.

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS